EP1876893A4 - Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase - Google Patents

Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase

Info

Publication number
EP1876893A4
EP1876893A4 EP06750227A EP06750227A EP1876893A4 EP 1876893 A4 EP1876893 A4 EP 1876893A4 EP 06750227 A EP06750227 A EP 06750227A EP 06750227 A EP06750227 A EP 06750227A EP 1876893 A4 EP1876893 A4 EP 1876893A4
Authority
EP
European Patent Office
Prior art keywords
proteasome
cancer treatment
combined inhibition
telomerase
telomerase activities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06750227A
Other languages
German (de)
English (en)
Other versions
EP1876893B1 (fr
EP1876893A2 (fr
Inventor
Malcolm A S Moore
Allison C Chin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Geron Corp
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Geron Corp
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research, Geron Corp, Memorial Sloan Kettering Cancer Center filed Critical Sloan Kettering Institute for Cancer Research
Publication of EP1876893A2 publication Critical patent/EP1876893A2/fr
Publication of EP1876893A4 publication Critical patent/EP1876893A4/fr
Application granted granted Critical
Publication of EP1876893B1 publication Critical patent/EP1876893B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP06750227A 2005-04-15 2006-04-14 Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase Active EP1876893B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67163005P 2005-04-15 2005-04-15
PCT/US2006/014137 WO2006113470A2 (fr) 2005-04-15 2006-04-14 Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase

Publications (3)

Publication Number Publication Date
EP1876893A2 EP1876893A2 (fr) 2008-01-16
EP1876893A4 true EP1876893A4 (fr) 2010-09-01
EP1876893B1 EP1876893B1 (fr) 2012-04-11

Family

ID=37115747

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06750227A Active EP1876893B1 (fr) 2005-04-15 2006-04-14 Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase

Country Status (4)

Country Link
US (1) US7998938B2 (fr)
EP (1) EP1876893B1 (fr)
AT (1) ATE553198T1 (fr)
WO (1) WO2006113470A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5686493B2 (ja) 2003-01-24 2015-03-18 ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ テロメアの長さを決定することによって死亡の危険性を予測する方法
ES2662196T3 (es) 2003-09-09 2018-04-05 Geron Corporation Oligonucleótidos modificados para la inhibición de la telomerasa
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
CN101484575B (zh) 2005-06-08 2013-10-02 森托科尔公司 用于眼变性的细胞疗法
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
WO2007127163A2 (fr) * 2006-04-24 2007-11-08 Geron Corporation Méthode et composition pour le traitement d'une tumeur du snc
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
MY147832A (en) 2006-06-19 2013-01-31 Onyx Therapeutics Inc Compounds for enzyme inhibition
EP3494975A1 (fr) * 2006-10-30 2019-06-12 Geron Corporation Inhibiteur de télomérase combiné et gemcitabine pour le traitement du cancer
EP2134364B1 (fr) * 2007-03-09 2013-02-13 Geron Corporation Traitement de carcinomes avec une combinaison d'inhibiteurs de voie egf et de telomerase
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
WO2009018453A1 (fr) 2007-07-31 2009-02-05 Lifescan, Inc. Différenciation de cellules souches embryonnaires humaines
KR20100088664A (ko) 2007-10-04 2010-08-10 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
CA3123528A1 (fr) 2007-11-27 2009-06-04 Lifescan, Inc. Differenciation de cellules souches embryonnaires humaines en cellules pancreatiques
KR20190057164A (ko) 2008-02-21 2019-05-27 얀센 바이오테크 인코포레이티드 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
ES2697798T3 (es) 2008-06-30 2019-01-28 Janssen Biotech Inc Diferenciación de células madre pluripotentes
ES2617560T3 (es) * 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple
BRPI0919883A2 (pt) 2008-10-31 2015-08-11 Centocor Ortho Biotech Inc Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
RU2522001C2 (ru) 2008-10-31 2014-07-10 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
WO2010059778A1 (fr) 2008-11-20 2010-05-27 Centocor Ortho Biotech Inc. Procédés et compositions pour adhésion cellulaire et culture sur des substrats plans
KR101837080B1 (ko) 2008-11-20 2018-03-09 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
AU2009329987B2 (en) 2008-12-22 2016-08-04 University Of Utah Research Foundation Monochrome multiplex quantitative PCR
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
BR112012001564A2 (pt) 2009-07-20 2015-09-01 Janssen Biotech Inc Diferenciação de células tronco embrionárias humanas.
MX340952B (es) 2009-07-20 2016-07-29 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
GB2484873B (en) 2009-07-20 2014-04-30 Janssen Biotech Inc Differentiation of pancreatic endoderm cells.
AU2010300259A1 (en) * 2009-10-01 2012-04-26 Janssen Pharmaceutica Nv Proteasome inhibitors for treating cancer
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
RU2610176C2 (ru) 2009-12-23 2017-02-08 Янссен Байотек, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
KR101923537B1 (ko) 2009-12-23 2018-11-29 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
MX358451B (es) 2010-03-01 2018-08-20 Janssen Biotech Inc Métodos para purificar células derivadas de células madre pluripotenciales.
CN107338217B (zh) 2010-05-12 2021-02-09 詹森生物科技公司 人胚胎干细胞的分化
US9506036B2 (en) 2010-08-31 2016-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2853589B1 (fr) 2010-08-31 2017-12-27 Janssen Biotech, Inc. Différenciation de cellules souches embryonnaires humaines
AU2011296383B2 (en) 2010-08-31 2016-03-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
MX2014007744A (es) 2011-12-22 2015-01-12 Janssen Biotech Inc Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal.
SG11201405052RA (en) 2012-03-07 2014-10-30 Janssen Biotech Inc Defined media for expansion and maintenance of pluripotent stem cells
SG11201408124PA (en) 2012-06-08 2015-01-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
CA2892445C (fr) 2012-11-30 2022-06-28 Geron Corporation Marqueurs de diagnostic pour le traitement de troubles de la proliferation cellulaire par des inhibiteurs de telomerase
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
KR101942769B1 (ko) 2012-12-31 2019-01-28 얀센 바이오테크 인코포레이티드 Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
WO2014105543A1 (fr) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culture de cellules souches embryonnaires humaines à l'interface air-liquide en vue de la différenciation en cellules endocrines pancréatiques
CA2912216A1 (fr) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Mesures de l'abondance de telomeres courts
EP3868772A1 (fr) * 2013-09-30 2021-08-25 Geron Corporation Liaison de squelette phosphorodiamidate pour oligonucléotides
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
AU2015259573B2 (en) 2014-05-16 2021-03-18 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
AU2015372584A1 (en) 2014-12-30 2017-06-29 Telomere Diagnostics, Inc. Multiplex quantitative PCR
US20180036331A1 (en) * 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
EP3318276A1 (fr) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
JP2023532199A (ja) * 2020-06-17 2023-07-27 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション プロテアソーム阻害剤治療のためのバイオマーカーに基づく患者選択

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
PL2548880T3 (pl) 2003-06-23 2019-07-31 Telomerase Activation Sciences, Inc. Kompozycje powodujące wzrost aktywności telomerazy
ES2662196T3 (es) * 2003-09-09 2018-04-05 Geron Corporation Oligonucleótidos modificados para la inhibición de la telomerasa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASAI AKIRA ET AL: "A novel telomerase template antagonist (GRN163) as a potential anticancer agent.", CANCER RESEARCH 15 JUL 2003 LNKD- PUBMED:12873987, vol. 63, no. 14, 15 July 2003 (2003-07-15), pages 3931 - 3939, XP002593248, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
ATE553198T1 (de) 2012-04-15
US7998938B2 (en) 2011-08-16
EP1876893B1 (fr) 2012-04-11
WO2006113470A2 (fr) 2006-10-26
US20100010064A1 (en) 2010-01-14
WO2006113470A3 (fr) 2006-12-14
EP1876893A2 (fr) 2008-01-16

Similar Documents

Publication Publication Date Title
EP1876893A4 (fr) Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
WO2008054711A3 (fr) Inhibiteur de télomérase combiné à la gemcitabine dans le traitement du cancer
MX2010006154A (es) Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
SG164368A1 (en) Treatment of cancer
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2010005221A (es) Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
MX2008016453A (es) Composiciones y metodos para tratar infecciones parasitas.
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
TWI367886B (en) Proteasome inhibitors and methods of using the same
HK1130438A1 (en) Using pi3k and mek modulators in treatments of cancer
WO2011031474A3 (fr) Utilisation de metformine dans le traitement et la prévention du cancer
TW200718689A (en) 2-Amino-quinazolin-5-ones
EA201391705A1 (ru) Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
TW200738263A (en) ANG2 and VEGF inhibitor combinations
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
WO2008030883A3 (fr) Traitement du cancer
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
WO2008112129A3 (fr) Traitement de carcinomes avec une combinaison d'inhibiteurs de voie egf et de télomérase
WO2009074968A3 (fr) Methode de prevision de l'efficacite d'un traitement anticancereux
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
JO3262B1 (ar) توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
WO2006113426A3 (fr) Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
WO2006124904A3 (fr) Traitement du cancer par inhibition combinee de telomerase et d'activites hsp90

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MOORE, MALCOLM, A., S.

Inventor name: CHIN, ALLISON, C.

A4 Supplementary search report drawn up and despatched

Effective date: 20100804

17Q First examination report despatched

Effective date: 20110321

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602006028791

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A01N0043040000

Ipc: C12N0015113000

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20110824BHEP

Ipc: A01N 61/00 20060101ALI20110824BHEP

Ipc: A61K 31/454 20060101ALI20110824BHEP

Ipc: A01N 43/04 20060101ALI20110824BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 553198

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006028791

Country of ref document: DE

Effective date: 20120606

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE S.A.

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 553198

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120411

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20120411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120813

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120430

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120712

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

26N No opposition filed

Effective date: 20130114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120722

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006028791

Country of ref document: DE

Effective date: 20130114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060414

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006028791

Country of ref document: DE

Representative=s name: BRINKMANN & PARTNER PATENTANWAELTE PARTNERSCHA, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006028791

Country of ref document: DE

Representative=s name: RAUSCH WANISCHECK-BERGMANN BRINKMANN PARTNERSC, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230309

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230307

Year of fee payment: 18

Ref country code: CH

Payment date: 20230502

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240312

Year of fee payment: 19

Ref country code: NL

Payment date: 20240315

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240229

Year of fee payment: 19